๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› NSCLC (Advanced Non-small Cell Lung Cancer)
Clinical trial register · China

NSCLC (Advanced Non-small Cell Lung Cancer) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 6 Beijing 5 Guangzhou 4 Hangzhou 3 Wuhan 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai6 Beijing5 Guangzhou4 Hangzhou3 Wuhan2
All 12 locations
Target enrolment
to

NSCLC (Advanced Non-small Cell Lung Cancer) trials in China

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Becotatug Vedotin Combined With Pucotenlimab ยฑ Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
NCT07627321NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital
Phase 2
39
Hefei
2026-07-15
Not yet open
GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
NCT07554859NSCLC (Advanced Non-small Cell Lung Cancer)
Genfleet Therapeutics (Shanghai) Inc.
Phase 2
90
Guangzhou
2026-05-20
Not yet open
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
NCT07560358NSCLC (Advanced Non-small Cell Lung Cancer)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
204
Beijing
2026-05-01
Not yet open
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
NCT07343479NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
Zhejiang Cancer Hospital
Phase 2
45
Hangzhou
2026-05-01
Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NCT07528274NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-05-01
Not yet open
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
NCT07469488NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
122
Shanghai
2026-04-30
Recruiting
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NCT07348965NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
Guangzhou University of Traditional Chinese Medicine
Not applicable
42
Guangzhou
2026-03-01
Recruiting
A Retrospective Real-World Study Based on RATIONALE-307
NCT07478809NSCLC (Advanced Non-small Cell Lung Cancer)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
109
Beijing
2026-02-28
Active, closed
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
NCT07669051NSCLC (Advanced Non-small Cell Lung Cancer)
Shandong Cancer Hospital and Institute
Phase 2
36
Jinan
2026-01-01
Recruiting
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT06992739NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
The First Affiliated Hospital of Xiamen University
Phase 2
49
Xiamen
2025-12-08
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Recruiting
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
NCT07330596NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital
Phase 2
96
Hefei
2025-10-30
Active, closed
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671NSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University
Observational
100
Shanghai
2025-10-16
Recruiting
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
NCT07250386NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hangzhou
2025-10-13
Active, closed
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC
NCT07703228NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, Second-line Therapy, Metastases
Nanfang Hospital, Southern Medical University
Phase 2
38
Guangzhou
2025-08-13
Recruiting
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
NCT06946927NSCLC (Advanced Non-small Cell Lung Cancer)
Jemincare
Phase 1
72
Guangzhou
2025-06-06
Recruiting
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
NCT06969612NSCLC (Advanced Non-small Cell Lung Cancer)
Peking University Cancer Hospital & Institute
Phase 1
21
Beijing
2025-05-15
Recruiting
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
NCT06775743NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University
Phase 2
53
Shanghai
2025-01-15
Recruiting
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NCT06956001EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Allist Pharmaceuticals, Inc.
Phase 3
300
Beijing, Shandong
2024-11-19
Recruiting
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
NCT06604689NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
Fudan University
Observational
800
Shanghai
2024-09-30
Active, closed
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
NCT07491211NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Osimertinib, Stereotactic Radiation
Fudan University
Observational
300
Shanghai, Wuhan
2019-07-19
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/nsclc-advanced-non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies listing the condition NSCLC (Advanced Non-small Cell Lung Cancer).

How many NSCLC (Advanced Non-small Cell Lung Cancer) trials are recruiting in China?

13 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (NSCLC (Advanced Non-small Cell Lung Cancer)), 24 studies
PhaseStudiesRecruitingShare
Phase 210441.7%
Observational5220.8%
Phase 14416.7%
Phase 3218.3%
Not applicable114.2%
Phase 1/2114.2%
Phase 4104.2%

Most active sponsors

Lead sponsors with the most studies (NSCLC (Advanced Non-small Cell Lung Cancer))
Lead sponsorStudiesRecruiting
Fudan University42
Anhui Provincial Cancer Hospital21
Cancer Institute and Hospital, Chinese Academy of Medical Sciences21
Allist Pharmaceuticals, Inc.11
Beijing Tide Pharmaceutical Co., Ltd11
Genfleet Therapeutics (Shanghai) Inc.10
Guangzhou University of Traditional Chinese Medicine11
Jemincare11
Nanfang Hospital, Southern Medical University10
Peking University Cancer Hospital & Institute11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.